Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day
On July 8, 2024, Nurix Therapeutics (Nasdaq: NRIX), a clinical-stage biopharmaceutical firm focused on developing targeted protein modulation drugs for cancer and inflammatory diseases, announced its participation in the UBS Virtual Targeted Protein Degradation (TPD) Day. Dr. Arthur T. Sands, Nurix's President and CEO, will engage in a fireside chat at 2:30 p.m. ET on July 15, 2024. The discussion will be webcast live and accessible through the Investors section of Nurix's website, under Events and Presentations, and the archived version will remain available for 30 days post-event.
- None.
- None.
SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the UBS Virtual Targeted Protein Degradation (TPD) Day, at 2:30 p.m. ET on Monday, July 15, 2024.
The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. The archived webcast will be available for 30 days after the event.
About Nurix
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
When will Nurix Therapeutics participate in the UBS Virtual TPD Day?
What time is the Nurix Therapeutics fireside chat at UBS Virtual TPD Day?
How can I access the Nurix Therapeutics webcast from the UBS Virtual TPD Day?
How long will the Nurix Therapeutics webcast be available after the UBS Virtual TPD Day?
What is the stock symbol for Nurix Therapeutics?
